Park et al. (2018) reported that the aqueous extracts of CR could inhibit human colorectal cancer cell viability by down-regulating cyclin D1 via GSK3β-dependent T286 phosphorylation and downregulation of β-catenin. Moreover, CR could also drive ROS-dependent apoptosis in human colorectal cancer cells. Pan et al. (2022) reported oral administration of CR inhibited the growth of colon cancer cells in C57BL/6 mice via Akt/ERK signaling pathways. The gene discussed is AKT1; the disease is colorectal cancer.